Preoperative neutrophil-to-lymphocyte ratio predicts response to first-line platinum-based chemotherapy and prognosis in serous ovarian cancer

Cancer Chemotherapy and Pharmacology

Volumn 75, Issue 2, 2016, Pages 255-262

  Wang, Ying ^a   Liu, Ping ^a   Xu, Yan ^a   Zhang, Weihao ^a   Tong, Lina ^a   Guo, Zhi ^a   Ni, Hong ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Chemotherapeutic sensitivity; Neutrophil to lymphocyte ratio; Prognosis; Serous ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; PLATINUM DERIVATIVE; PLATINUM COMPLEX;

ADULT; ADVANCED CANCER; ARTICLE; BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL FEATURE; CYTOREDUCTIVE SURGERY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG RESPONSE; FEMALE; GYNECOLOGIC SURGERY; HUMAN; HUMAN CELL; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; NEUTROPHIL LYMPHOCYTE RATIO; OVARY CANCER; OVERALL SURVIVAL; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SEROUS OVARIAN CANCER; AGED; BLOOD; DISEASE FREE SURVIVAL; FOLLOW UP; LYMPHOCYTE COUNT; MIDDLE AGED; NEUTROPHIL; OVARIAN NEOPLASMS; PREDICTIVE VALUE; PROGNOSIS; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOCYTE COUNT; MIDDLE AGED; NEUTROPHILS; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; PREOPERATIVE PERIOD; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84926124984     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2622-6     Document Type: Article

References (26)

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics 2013. CA Cancer J Clin 63(1):11-30. doi:10.3322/caac.21166
2. Kobel M, Kalloger SE, Huntsman DG, Santos JL, Swenerton KD, Seidman JD, Gilks CB (2010) Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol 29(3):203-211. doi:10.1097/PGP.0b013e3181c042b6
3. Alkema NG, Tomar T, van der Zee AG, Everts M, Meersma GJ, Hollema H, de Jong S, van Vugt MA, Wisman GB (2014) Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer. Gynecol Oncol 133(3):591-598. doi:10.1016/j.ygyno.2014.03.557
4. Cohen S, Mosig R, Moshier E, Pereira E, Rahaman J, Prasad-Hayes M, Halpert R, Billaud JN, Dottino P, Martignetti JA (2014) Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma. Gynecol Oncol. doi:10.1016/j.ygyno.2014.06.025
5. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420(6917):860-867. doi:10.1038/nature01322
6. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646-674. doi:10.1016/j.cell.2011.02.013
7. Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ (2005) Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 91(3):181-184. doi:10.1002/jso.20329
8. Azab B, Shah N, Radbel J, Tan P, Bhatt V, Vonfrolio S, Habeshy A, Picon A, Bloom S (2013) Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients. Med Oncol 30(1):432. doi:10.1007/s12032-012-0432-4
9. Cho IR, Park JC, Park CH, Jo JH, Lee HJ, Kim S, Shim CN, Lee H, Shin SK, Lee SK, Lee YC (2014) Pre-treatment neutrophil to lymphocyte ratio as a prognostic marker to predict chemotherapeutic response and survival outcomes in metastatic advanced gastric cancer. Gastric Cancer. doi:10.1007/s10120-013-0330-2
10. Choi ES, Kim HS, Han I (2014) Elevated preoperative systemic inflammatory markers predict poor outcome in localized soft tissue sarcoma. Ann Surg Oncol 21(3):778-785. doi:10.1245/s10434-013-3418-3
11. Xue P, Kanai M, Mori Y, Nishimura T, Uza N, Kodama Y, Kawaguchi Y, Takaori K, Matsumoto S, Uemoto S, Chiba T (2014) Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients. Cancer Med 3(2):406-415. doi:10.1002/cam4.204
12. Sharaiha RZ, Halazun KJ, Mirza F, Port JL, Lee PC, Neugut AI, Altorki NK, Abrams JA (2011) Elevated preoperative neutrophil:lymphocyte ratio as a predictor of postoperative disease recurrence in esophageal cancer. Ann Surg Oncol 18(12):3362-3369. doi:10.1245/s10434-011-1754-8
13. Ohno Y, Nakashima J, Ohori M, Hatano T, Tachibana M (2010) Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with non-metastatic renal cell carcinoma. J Urol 184(3):873-878. doi:10.1016/j.juro.2010.05.028
14. Cho H, Hur HW, Kim SW, Kim SH, Kim JH, Kim YT, Lee K (2009) Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother 58(1):15-23. doi:10.1007/s00262-008-0516-3
15. Williams KA, Labidi-Galy SI, Terry KL, Vitonis AF, Welch WR, Goodman A, Cramer DW (2014) Prognostic significance and predictors of the neutrophil-to-lymphocyte ratio in ovarian cancer. Gynecol Oncol 132(3):542-550. doi:10.1016/j.ygyno.2014.01.026
16. Thavaramara T, Phaloprakarn C, Tangjitgamol S, Manusirivithaya S (2011) Role of neutrophil to lymphocyte ratio as a prognostic indicator for epithelial ovarian cancer. J Med Assoc Thail 94(7):871-877
17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205-216
18. Vergote I, Rustin GJ, Eisenhauer EA, Kristensen GB, Pujade-Lauraine E, Parmar MK, Friedlander M, Jakobsen A, Vermorken JB (2000) Re: new guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). Gynecologic Cancer Intergroup. J Natl Cancer Inst 92(18):1534-1535
19. Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140(6):883-899. doi:10.1016/j.cell.2010.01.025
20. Wang Y, Niu XL, Qu Y, Wu J, Zhu YQ, Sun WJ, Li LZ (2010) Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cancer Lett 295(1):110-123. doi:10.1016/j.canlet.2010.02.019
21. Ferrandina G, Lauriola L, Zannoni GF, Fagotti A, Fanfani F, Legge F, Maggiano N, Gessi M, Mancuso S, Ranelletti FO, Scambia G (2002) Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann Oncol 13(8):1205-1211
22. Asher V, Lee J, Innamaa A, Bali A (2011) Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer. Clin Transl Oncol 13(7):499-503. doi:10.1007/s12094-011-0687-9
23. Banerjee S, Rustin G, Paul J, Williams C, Pledge S, Gabra H, Skailes G, Lamont A, Hindley A, Goss G, Gilby E, Hogg M, Harper P, Kipps E, Lewsley LA, Hall M, Vasey P, Kaye SB (2013) A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG. Ann Oncol 24(3):679-687. doi:10.1093/annonc/mds494
24. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454(7203):436-444. doi:10.1038/nature07205
25. Kusumanto YH, Dam WA, Hospers GA, Meijer C, Mulder NH (2003) Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis 6(4):283-287. doi:10.1023/B:AGEN.0000029415.62384.ba
26. Smyth MJ, Dunn GP, Schreiber RD (2006) Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 90:1-50. doi:10.1016/S0065-2776(06)90001-7